Healthcare AI faces reality check: proof over promises

By 2026, healthcare AI leaders had narrowed the definition of useful AI from impressive demos to domain-specific systems that could change decisions inside care delivery. Abridge’s leadership described clinical AI as software that can bend decisions, help clinicians choose MRI over CT, and recognize that one patient sounds like 10,000 other patients, while EUVC framed the standard in task-level terms, saying its symphony outperforms every one of them with more than 25% on medical coding.

That sharper standard emerged after general-purpose experiments disappointed. Thoughts on Healthcare Markets and Technology said the mid-2020s shifted attention from foundation-model pilots to specialized, clinically validated approaches, noting that health system CIOs who jumped on foundation models in 2023 spent 2024 explaining to their boards why pilot projects did not scale despite impressive demos, and that OpenAI launched ChatGPT Health in January 2025 with Color Health and bwell Connected Health because healthcare requires different architecture, training approaches, and go-to-market strategies. By late August 2026, Black Book Research had codified converged clinical AI around workflow execution and evidence traceability, and its August 24, 2026 market assessment and 2027 outlook described an operating intelligence layer between the longitudinal patient record, the clinician, the EHR and the revenue cycle, while Linear’s analysis said AI that prevents a $30,000 hospitalization is not a nice-to-have.

What changed is not just enthusiasm for AI, but the economic bar buyers now set. On the New York Stock Exchange, Hinge Health said that when asked, “What are you hearing from employers and health plans right now?” the answer was blunt: “Costs are too high… healthcare in America is expecting its largest cost increase in about 15 years in 2026… Double-digit” increases, pushing purchasers toward tools that can prove savings and fit care operations, while Sword Health’s CEO argued that the winners will be companies using technology as the care model itself, “not technology as the core driver… If you're going to see a 10, 20, $50 billion company… it's going to be one of those companies.”

That demand is now reinforced by evidence, integration requirements, and trust thresholds. According to Thoughts on Healthcare Markets and Technology, “At the application layer… The outcomes data being cited at HIMSS26 is real and measurable… Prior auth time cut by 42%… Denials reduced by 20%… Fifteen billion in prevented claim losses,” while ISG said “enterprises are moving from pilot deployments to structured, enterprise-wide AI adoption aligned with broad operational strategies”; investors likewise described an “emerging area… AI and clinical services” built on deterministic use cases that “trust to actually augment the doctor or the nurses,” and even the headline “Anthropic and OpenEvidence Deploy Free AI Clinical Support to 100 Low‑Income Nations” reflects the pull toward clinically grounded, specialized systems.

For buyers, the winning AI pitch is no longer technical novelty but a budget-line case that survives finance review. Upward Growth says health plans judge vendors on PMPM cost, MLR, admin ratio, Stars, HEDIS, risk adjustment, and retention, and even recommends modeling ROI at “three attainment levels: 100%, 70%, and 50% of your projected outcome” while tying payback to the fiscal year because “Plans heavily discount future-year payback”; that is why “Our model predicts…87% accuracy” loses to “saving an average of $1.80 PMPM… roughly $6.5M in annual savings.”

Operational and governance screens now weigh as heavily as economics, especially once AI is embedded in care pathways and hard to unwind. Digital Health Wire notes that “None of the four companies has published product-specific performance numbers,” while the “only independent evaluation” found “ChatGPT Health under-triaging 52% of gold-standard emergencies,” and warns that Epic “became default infrastructure before governance caught up… and its sepsis model needed 109 alerts to find one true case”; inside health systems, that caution matches budget reality, with The 229 Podcast reporting, “In Portland, 65% of this room says their number one challenge is competing priorities and capacity.”

OpenEvidence is one of the clearest signs that vertical AI is already scaling in healthcare. Linear described it as a “vertical AI search tool for physicians” that reached “40%+ of all U.S. doctors using their platform by mid-2025,” then added “another 100K+ doctors,” for roughly 440,000+ physicians. Vincent Private Markets said the product grew through “word of mouth” and bottom-up adoption, while its economics moved with usage, reporting that it “hit 50 in the summer this year and then… 150 just very recently” through advertising tied to “very high intent” clinician queries.

That adoption is translating into measurable value, not just attention. Vincent Private Markets contrasted OpenEvidence with UpToDate by noting hospitals pay “$500 a seat” for incumbent reference access while “open evidence is free,” and Linear said the company generated “$150M in annualized ad revenue — up from zero,” with “90%+ gross margins on ad revenue,” and that its valuation doubled “from $6B to $12B” only after “massive adoption FIRST.” Embold reported up to 5.46% lower per-member costs across 325,000 covered lives and estimated $5.5 million in annual savings for a 10,000-employee employer, while Business Wire reported that Quantum Health acquired Embold in June 2025 to combine “complementary capabilities” and improve navigation at scale.

Clinician skepticism remains high because many tools still cannot prove, in real clinical conditions, that their answers are dependable enough for decisions where mistakes carry patient risk. WION reported that a 2026 survey found 74 per cent of clinicians worried about deskilling and the same share worried about AI inventing false information, underscoring a double fear: that hallucinations can introduce error, and that reliance on AI can erode the human judgment needed to catch those failures when they matter most.

That skepticism persists partly because healthcare still lacks clean, trusted ways to evaluate many AI systems outside narrow tasks with obvious right answers. As a16z argued, medicine has no shared absolute ground truth, benchmarks often reflect what one physician did rather than what is definitively correct, and the only objective test may be following patients over time; against that backdrop, companies such as Doctronic end up leaning on proxy trust signals, tracking “how long people are actually chatting with the system,” with “8 to 10, up to 20 minute engagement times,” plus return visits as “basically a vote of confidence.”